A detailed history of Geode Capital Management, LLC transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 84,826 shares of XLO stock, worth $80,584. This represents 0.0% of its overall portfolio holdings.

Number of Shares
84,826
Previous 84,826 -0.0%
Holding current value
$80,584
Previous $46,000 97.83%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$2.11 - $2.9 $211 - $290
100 Added 0.12%
84,826 $178,000
Q4 2022

Feb 13, 2023

BUY
$1.97 - $2.72 $2,239 - $3,092
1,137 Added 1.36%
84,726 $227,000
Q2 2022

Aug 12, 2022

SELL
$2.08 - $7.2 $120,891 - $418,471
-58,121 Reduced 41.01%
83,589 $244,000
Q1 2022

May 13, 2022

BUY
$6.63 - $16.05 $49,890 - $120,776
7,525 Added 5.61%
141,710 $1 Million
Q4 2021

Feb 11, 2022

BUY
$9.69 - $25.11 $1.3 Million - $3.37 Million
134,185 New
134,185 $2.15 Million

Others Institutions Holding XLO

About Xilio Therapeutics, Inc.


  • Ticker XLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,471,600
  • Market Cap $26.1M
  • Description
  • Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...
More about XLO
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.